Lanthionine antibiotic compositions and methods

Details Lanthionine antibiotic compositions and methods Lanthionine antibiotic compositions and methods

2004-03-02

2010-02-02

Ford, Vanessa L. (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C424S244100, C424S400000, C424S404000, C424S422000, C424S486000, C530S300000, C530S325000

Reexamination Certificate

active

07655236

ABSTRACT:
According to the present invention, an isolated and purified DNA sequence which encodes a lantibiotic, mutacin I, is disclosed. The nucleic acid sequence is set forth in SEQ ID No: 1 and the amino acid sequence is set forth in SEQ ID No: 2.

REFERENCES:
patent: 4554101 (1985-11-01), Hopp et al.
patent: 4603102 (1986-07-01), Himmelmann et al.
patent: 4740593 (1988-04-01), Gonzalez et al.
patent: 4980163 (1990-12-01), Blackburn et al.
patent: 5043176 (1991-08-01), Bycroft et al.
patent: 5135910 (1992-08-01), Blackburn et al.
patent: 5932469 (1999-08-01), Hillman
patent: 6218362 (2001-04-01), Lavoic et al.
patent: 6391285 (2002-05-01), Hillman
patent: WO 92/18143 (1992-10-01), None
patent: WO 93/01987 (1993-09-01), None
patent: WO 98/56411 (1998-12-01), None
Kyd et al, (Vaccine 18 (2000), 398-406)).
(Samukawa et al, (The Journal of Infectious Diseases, 2000, 181:1842-5).
(Gu et al, Infection and Immunity, May 1998, p. 1891-1897).
Odeh (Cytokine, Apr. 7;14(1):11-8).
Fox (Biotechnology, vol. 12, Feb. 1994).
Sartor (Gasreoenterology Clinic of North America (United States), Sep. 1995, 24, p. 475-507).
Braegger (Acta Paediatr Suppl. 395: 18-21, 1994).
Fox et al (Infection and Immunity, Apr. 1999, p. 1757-1762.
Rodriguez et al (Journal of General Microbiology, 1992, vol. 138, No. 2, p. 269-274).
Koch et al (Vaccine 22, 2004, pp. 822-830).
O'Brien et al (American Family Physicians, May 1, 2003, 67, 9).
Loyola Rodriguez et al (Journal of General Microbiology, 1992, vol. 138, No. 2, p. 269-274).
O'Brien et al (American Family Physicians, May 1, 2003, 67, 9.
Ikeda et al (Infection and Immunity, 1982, vol. 35, No. 3, p. 861-868).
Ooshima et al (Microbiol. Immunol., vol. 29 (12), 1163-1173, 1985).
MedicineNet.com (http://www.medterms.com/script/main/art) (accessed Aug. 3, 2006.
Thomas E. Creighton, in his book, “Proteins: Structures and Molecular Properties, 1984”, (pp. 314-315).
Thomas E. Creighton, in his book “Protein Structure: A Practical Approach, 1989; pp. 184-186”.
Nosoh, Y. et al in “Protein Stability and Stabilization through Protein Engineering, 1991” (chapter 7, p. 197, second paragraph).
Chen et al., Applied and Environmental Microbiology, Mar. 1999, p. 1336-1360.
Hamada et al., Archs Oral Biol, vol. 20, p. 641-648.
Augustin et al. (1992) “Genetic analysis of epidermin biosynthetic genes and epidermin-negative mutants ofStaphylococcus epidermis”, Eur. J. Biochem, 204:1149-1154.
Bedwell et al. (1989) “Sequrence and Structural Requirements of a Mitochondrial Protein Import Signal Defined by Saturation Cassette Matugenesis”, Mol. Cell. Biol., 9:1014-1025.
Buchman et al. (1988) “Structure, Expression, and Evolution of a Gene Encoding the Precursor of Nisin, A Small Protein Antibiotic”, J. Biol. Chem., 263:16260-16266.
Burdett (1990) “Nucleotide sequence of the tet(M) gene of Tn916”, Mucl. Acid Res., 18:6137.
Caufield et al. (1990) “Evidence that Mutacin II production is not mediated by a 5.6-kb plasmid inStreptococcus mutans”, Plasmid, 24:110-118.
Caufield et al. (1990) “Use of transposon Tn916 to inactivate isolate a mutacin-associated gene fromStreptococcus mutans”, Infection and Immunity, 58(12):4126-4135.
Caufield et al. (1985) “Distinct bacteriocin groups correlate with different groups ofStreptococcus mutansplasmids”, Infection and Immunity, 48(1): 51-56.
Chikindas, M.L. et al. (1994) “Mutacin II, a bactericidal lantibiotic from streptoccus mutans”, Antimicrobial Agents and Chemotherapy, 39(12):2645-2660.
Chou and Fasman (1975a) “Prediction of Protein Conformation”, Biochemistry, 13(2):222-245.
Chou and Fasman (1974b) “Conformational Prameters ofr Amino Acids in Helical, β-Sheet, and Random Coil Regions Calculated from Proteins”, Biochemistry, 13(2):211-222.
Chou and Fasman (1978a) “Prediction of the Secondary Structure of Proteins from Their Amino Acid Sequence,” Adv. Enzymol. Relat. Areas Mol. Biol. 47:45-148.
Chou and Fasman (1978b) “Empirical Predictions of Protein Conformation”, Ann. Rev. Biochem., 47:251-276.
Chung and Hansen (1992) “Determination of the Sequence of spaE and Identification of a Promoter in the Subtilin (spa) Operon in Bacillus Subtilit”, J. Bacteriol. 174:6699-6702.
Dodd et al. (1990) “Analysis of the genetic determinant for production of the peptide antibiotic nisin”, J. Gen. Microbiol., 136:555-566.
Gawron-Burke and Clewell (1984) “Regeneration of Insertionally INactivatedStreptococcalDNA Fragments after Excision of Transposon Tn916 inEscherichia coli: Strategy for Targeting and Cloning of Genes from Gram-Positive Bacteria”, J. Bacteriol., 159:214-221.
Bross and Kiltz (1973) “The Number and Nature of a, β-Unsaturated amino Acids in Subtilin”, Biochem. Biophys. Res. Commun., 50:559-565.
Hillman, J.D. et al. (1988) “Genetic and Biochemical Analysis of Mutacin 1140, a Lantibiotic fromStreptococcus mutans”, Infection and Immunity, 66(6):2743-2749.
Horinouchi and Weisblum (1982) “Nucleotide Sequence and Functional Map of pC194, a Plasmid that Specifies Inducible Chloramphenicol Resistance”, J. Bacteriol., 150:815-825.
Honr et al. (1991) “Nisin biosynthesis genes are encoded by a novel conjugative tranposon” Mol. Gen. Genet., 228:129-135.
Jakes et al. (1988) “A Hybrid Toxin from Bacteriophage f1 Attachment Protein and Colocin E3 has Altered Cell Receptor Specificity”, J. Bacteriol, 170(9):4231-4238.
Kaletta and Entian (1989) “Nisin, a peptide antibiotic: cloning and sequencing of the nisA gene and prosttranslational processing of its peptide product”, Journal of Bacteriology, 171(3):1597-1601.
Kyte and Doolittle (1982) “A Simple Method for Displaying the Hydropathic Character of a Protein”, J. Mol. Biol. 157(1):105-132.
LeBlanc et al. (1988) “Nucleotide Sequence Analysis of Tetracycline Resistance Gene tetO fromStreptococcus mutansDL5”, J. Bacteriol., 170(*):3618-3626.
Liu and Hansen (1992) “Enhancement of the chemical and antimicrobial properties of subtilin by site-directed mutagenesis”, J. Biol. Chemistry, 267(35):25078-25085.
Liu and Hansen (1991) “conversion ofBacillus subtilis168 to a Subtilin Producer by Competence Transformation”, J. Bacteriol., 173(22):7387-7390.
Loyola-Rodriquez et al. (1992) “Purification and properties of extracellular mutacin, a bacteriocin fromStreptococcus sobrinus”, J. Gen. Microbiology, 138:269-274.
Macrina et al. (1977), “Survey of the Extrachromosomal Gene pool ofStreptococcus Mutans”, Infect. Immun., 17(1):215-226.
Miller et al. (1991) “Quantition of Type I, II, and V Collagens in Human Tissue Samples by High-Performance Liquid Chromatography of Selected Cyanogen Bromide Peptides”, Anal. Biochem. 196:54-60.
Miller et al. (1990) “Amino Acid Analysis of Collagen Hydrolysates by Reverse-Phase High-Performance Liquid Chromatography of i-Fluorenyllmethyl Chloroformate Derivates”, Anal. Biochem., 190:92-97.
Nakano and Kuranmitsu (1992) “Mechanixm ofStreptococcus mutansGlucosyltransferases: Hybrid-Enzyme Analysis”, J. Bacteriol. 174(17):5639-5646.
Novak et al. (1996) “Detection of Modified Amino Acids in Lantibiotic Peptide Mutacin II by Chemical Derivatization and Electrospray Ionization—Mass Spectroscopic Analysis”, Analytic Biochemistry, 236:358-360.
Novak et al. (1994) “iIsolation and biochemical characterization of a novel lantibiotic mutacin fromStreptococcus mutans”, J. Bacteriol., 176(14):4316-4320.
Novak et al. (1994) “Genetic and biochemical characterization of a novel lantibiotic fromStreptococcus mutans”, 7th Internationl Congress of Bacteriology and Applied Microbiology Division, Jul. 3-8, 1994.
Novak et al. (1993) “Biochemical Analysis of a Group II mutacin from Stsreptococcus mutans”, 93

Affiliated with

Also associated with

Rating

Lanthionine antibiotic compositions and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Lanthionine antibiotic compositions and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lanthionine antibiotic compositions and methods will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4182803